Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).

被引：0
|
作者：
Terpos, Evangelos
Badros, Ashraf
Popat, Rakesh
Rodriguez-Otero, Paula
Farooq, Asim
Jeng, Bennie
Esposti, Simona Degli
Lewis, Eric
Gupta, Ira
Opalinska, Joanna
Palumbo, Antonio
Trudel, Suzanne
机构：
[1] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[3] Univ Coll London Hosp, NHS Fdn Trust, London, England
[4] Clin Univ Navarra, Inst Invest Sanitaria Navarra, Navarra, Spain
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[7] UCL Inst Ophthalmol, London, England
[8] GlaxoSmithKline, Res Triangle Pk, NC USA
[9] GlaxoSmithKline, Upper Providence, PA USA
[10] GlaxoSmithKline, Zug, Switzerland
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8033
引用
收藏
页数：4
相关论文
共 34 条
  • [31] A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)
    Weisel, Katja
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Gabor, Mikala
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Boyle, Julia
    Opalinska, Joanna
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S505
  • [32] No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Lowther, Daniel E.
    Houseman, E. Andres
    Han, Gang
    Kleanthous, Eleni
    Knoblock, Dawson
    Zhou, Xiangdong
    Banerjee, Shreyan
    Patel, Sagar
    Figueroa, David
    BLOOD, 2022, 140
  • [33] A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.
    Weisel, Katja
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Boyle, Julia
    Opalinska, Joanna
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors and Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics
    Lonial, Sagar
    Lee, Hans Chulhee
    Badros, Ashraf
    Trudel, Suzanne
    Nooka, Ajay K.
    Chari, Ajai
    Abdallah, Al-Ola
    Callander, Natalie Scott
    Sborov, Douglas Weston
    Suvannasankha, Attaya
    Weisel, Katja
    Voorhees, Peter M.
    Hultcrantz, Malin
    Libby, Edward N.
    Richardson, Paul G.
    Otero, Paula Rodriguez
    Besemer, Britta
    Facon, Thierry
    Hoos, Axel
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Jewell, Roxanne C.
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S301 - S302
1234